Association Between Framingham Risk Score, hsCRP and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography

Framingham risk score is well known screening tool that detect cardiovascular (CV) risk. But it is not suitable for CV risk in mild risk group. So 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a new imaging technique for detecting vascular inflammation within atherosclerotic plaques and hsCRP is also arising detection tool of CV risk.

The investigators are examining this association in normal and impaired glucose tolerance patients groups.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Risk Arterial Occlusive Diseases Arteriosclerosis Atherosclerosis Cardiovascular Diseases Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

16 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Korea university guro hospital

Seoul, South Korea

About this study

We examined vascular inflammation using FDG-PET scan in 178 subjects (Normal and impaired glucose tolerance groups). Vascular 18F-FDG uptake was measured as both the mean and maximum blood-normalized standardized uptake value (SUV), known as the target-to-background ratio (TBR). And We analyzed that the association with Framingham risk score, hs CRP and vascular inflammation by FDG-PET scan.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

healthy subjects

Exclusion criteria

a history of cardiovascular disease (myocardial infarction, unstable angina, stroke or cardiovascular revascularization)
active inflammatory disease, recent active infection
stage 2 hypertension (resting blood pressure, ≥ 160/100 mmHg)
diabetes mellitus
systemic disorders such as severe hepatic, renal, and hematologic diseases
taking drugs known to interfere with vascular inflammation measured by FDG-PET.

Sponsors and collaborators

Lead sponsor

Korea University Guro Hospital

Other

Registry information

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: Jun 9, 2010
Registry last updated: Jun 9, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed